Page 12 - hypertension_newsletter3

REFLECTIONS rtensio n
Hypertension Global Newsletter #3
n oisnetr
Hype
Hype

“We found there was a significant effect of treatment in lowering the odds of dementia associated with a sustained reduction
in blood pressure in this older population. Our results imply a broadly linear relationship between blood pressure reduction
and lower risk of dementia, regardless of which type of treatment was used. Our study provides the highest grade of available
evidence to show that blood pressure lowering treatment over several years reduces the risk of dementia, and we did not see any
evidence of harm.”
Dr. Ruth Peters, Lead Author
Quote taken from: https://neurosciencenews.com/blood-pressure-dementia-21721/

CLICK HERE
FOR THE LINK TO FULL ARTICLE

ACRONYMS:
AA, aldosterone antagonist; ACEi, angiotension-converting enzyme inhibitor; aHR, adjusted hazard ratio; AMI, acute myocardial
infarction; AF, atrial fibrillation; ARB, angiotensin receptor blockers; BB, beta blocker; bid, twice daily; BMI, body mass index; BP,
blood pressure; CCB, calcium channel blocker; CI, confidence interval; CKD, chronic kidney disease; CV, cardiovascular; CVD,
cardiovascular disease; DAMP, damage-associated molecular patterns; DBP, diastolic blood pressure; DPOH, delayed or prolonged
orthostatic hypotension; eGFR, estimated glomerular filtration rate; EOH, early orthostatic hypotension; HHD, hypertensive heart
disease; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction;
HMOD, hypertension-mediated organ damage; HR, hazard ratio; LA left atrial; LV, left ventricular; LVH, left ventricular hypertrophy;
MACE, major adverse cardiovascular events; MBP, mean arterial blood pressure; MI, myocardial infarction; MIF, myocardial
interstitial fibrosis; MRI, magnetic resonance imaging; NO, nitric oxide; OR, odds ratio; OSAS, obstructive sleep apnea syndrome;
PICP, carboxy-terminal propeptide of procollage type I; PP, pulse pressure; RAAS, renin-angiotensin-aldosterone system; RCT,
randomized controlled trial; RH, resistant hypertension; SBP, systolic blood pressure; SD, standard deviation; SNS, sympathetic
nervous system; T2D, type 2 diabetes; tid, three times daily.

ARTICLES OF INTEREST

PATHOPHYSIOLOGY

1. Revascularization for renovascular disease: A scientific statement from the American Heart Association. Bhalla V, et
al. Hypertension. 2022 Aug;79(8):e128-e143. https://pubmed.ncbi.nlm.nih.gov/35708012

2. Genetically predicted blood pressure, antihypertensive drugs and risk of heart failure: A Mendelian randomization
study. Lian J, et al. J Hypertens. 2022 Sep 14. doi: 10.1097/HJH.0000000000003297. Online ahead of print. https://pubmed.
ncbi.nlm.nih.gov/36129112

3. The interaction of estimated glomerular filtration rate with circadian blood pressure variation: Do not
forget the impact of albuminuria. Georgianos PI, et al. J Hypertens. 2022 Jul 1;40(7):1432-1433. doi: 10.1097/
HJH.0000000000003149. https://pubmed.ncbi.nlm.nih.gov/35762484

4. Home blood pressure monitoring schedule: Optimal and minimum based on 2122 individual participants’ data.
Kyriakoulis KG, et al. J Hypertens. 2022 Jul 1;40(7):1380-1387. doi: 10.1097/HJH.0000000000003157. https://pubmed.ncbi.
nlm.nih.gov/35762478

5. Gut microbiota: Friends or foes for blood pressure-lowering drugs. Zheng T, Marques FZ. Hypertension. 2022
Aug;79(8):1602-1604. https://pubmed.ncbi.nlm.nih.gov/35861751

6. Practical guide for the management of hypertensive disorders during pregnancy. Antza C, et al. J Hypertens. 2022 Jul
1;40(7):1257-1264. https://pubmed.ncbi.nlm.nih.gov/35762468

TABLE OF CONTENTS